Investors of Capricor Therapeutics, Inc. Take Note
Capricor Therapeutics, Inc. (NASDAQ: CAPR) finds itself at the center of a securities fraud class action lawsuit reminding investors to pay attention to an approaching deadline. Bernstein Liebhard LLP, a prominent law firm devoted to investor rights, is urging all investors of the company to understand their rights and the ongoing legal developments.
Understanding the Class Action Lawsuit
The lawsuit targets Capricor, alleging that the company, alongside some of its senior officers, violated the Securities Exchange Act of 1934. It primarily concerns investors who purchased shares between October 9, 2024, and July 10, 2025. These investors are advised to act swiftly to protect their rights.
Who Should Join?
If you bought shares of Capricor Therapeutics within the specified timeframe and believe you may have suffered financial losses, it is crucial to evaluate your options. Understanding whether you qualify to join this lawsuit can be imperative to your financial future.
Timeline for Action
Those interested in taking a role as a lead plaintiff in this case should file the necessary documentation by September 15, 2025. Acting as a lead plaintiff means representing the interests of all class members and guiding the litigation process.
Details of the Allegations
The basis of the lawsuit lies in claims that Capricor misrepresented crucial data regarding the safety and efficacy of its lead cell therapy candidate, deramiocel. This therapy aims to treat cardiomyopathy in patients with Duchenne muscular dystrophy. Investors are advised to closely follow developments, as these allegations may significantly influence the company's future.
Legal Fees and Representation
Importantly, any representation in this lawsuit will operate on a contingency fee basis. This means that shareholders will not incur out-of-pocket expenses during the legal proceedings. The firm only charges fees if they successfully recover funds for the investors involved.
What Happens if You Don't Take Action?
If you choose not to participate, you may remain an absent class member. This status may limit your ability to recover any potential damages. Therefore, participating actively could provide avenues for compensation should the lawsuit yield a favorable verdict.
About Bernstein Liebhard LLP
Since its establishment in 1993, Bernstein Liebhard LLP has an impressive track record, recovering over $3.5 billion for its clients. The law firm specializes in class action lawsuits and has a reputation for effectively representing both individual and institutional investors.
Investor Support and Resources
If you have any questions about your rights as a shareholder or how best to navigate this situation, please reach out to the Investor Relations Manager, Peter Allocco. He is readily available to assist and guide you through the process.
Frequently Asked Questions
What is the deadline to join the class action lawsuit?
The deadline to file papers to serve as a lead plaintiff is September 15, 2025.
Who can join the lawsuit?
Investors who purchased shares of Capricor Therapeutics between October 9, 2024, and July 10, 2025, may participate.
What are the financial implications of the lawsuit?
If successful, affected investors may recover damages resulting from financial losses attributed to the alleged misrepresentations.
Are there any costs involved in joining the lawsuit?
No, representation in this case is on a contingency fee basis, so investors will not incur costs unless recovery is achieved.
How do I contact Investor Relations for more information?
You can reach out to Peter Allocco at (212) 951-2030 for any inquiries regarding your rights as a shareholder.
